Merck, a renowned science and technology enterprise, has announced the appointment of Michael Kleinemeier (66) as the Chair of its Supervisory Board. Kleinemeier, who previously served as a member of…
Sanofi’s Leading Role in Addressing Inflammatory Diseases Highlighted at AAAAI Conference The latest data presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting sheds light on…
Eli Lilly and Company (NYSE:LLY) has announced that Philip Johnson, the group vice president and treasurer, will be retiring from the company after more than 28 years of service. His…
New data indicate that treatment with Nexviazyme® (avalglucosidase alfa) has significantly improved ptosis, or drooping eyelid, in pediatric patients with infantile-onset Pompe disease (IOPD) over nearly three years. These findings,…
The American Cancer Society (ACS) and Pfizer Inc. (NYSE: PFE) have jointly unveiled the “Change the Odds: Uniting to Improve Cancer Outcomes™” initiative, a three-year program aimed at addressing disparities…
Novartis has announced its intent to initiate a voluntary public takeover offer for the acquisition of MorphoSys AG (FSE: MOR; NASDAQ: MOR), a global biopharmaceutical company headquartered in Germany, specializing…
Merck Animal Health, operating as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), headquartered in Rahway, N.J., USA, has officially…
Novo Nordisk has announced its agreement to acquire three fill-finish sites from Novo Holdings A/S as part of the transaction where Novo Holdings will acquire Catalent, Inc., a global contract…
Eli Lilly and Company (NYSE: LLY) disclosed its financial outcomes for the final quarter of 2023, marking a year of notable accomplishments characterized by substantial revenue growth. David A. Ricks,…
Encouraging Outcomes in Japan Phase III Trial of Acoramidis for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Consistent with Global ATTRibute-CM Phase III Trial Positive high-level results from the Japan Phase III trial…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central…
Biogen to Reallocate Resources for Alzheimer’s Disease Franchise Growth Strategy” Biogen Inc. (Nasdaq: BIIB) has unveiled plans to strategically reallocate resources in the Alzheimer’s disease (AD) therapeutic area to drive…